3SBio Inc - Company Profile

Powered by

All the data and insights you need on 3SBio Inc in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date 3SBio Inc Strategy Report

  • Understand 3SBio Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

3SBio Inc: Overview

Select Item

Related keylists

3SBio Inc (3SBio) is a biotechnology company that discovers, develops, manufactures and markets biopharmaceutical products. The company develops recombinant or genetically engineered, protein-based products and other pharmaceutical product candidates to meet significant unmet medical needs in the areas of cancer and its supportive care, nephrology, dermatology, and other disease conditions. The company distributes its products to hospitals, clinics and dialysis centers in China. The company sells its products in Colombia, Brazil, Costa Rica, Egypt, Dominican Republic, Guatemala, El Salvador, Mongolia, Laos, Pakistan, Sri Lanka, Myanmar, the Philippines, Paraguay, Thailand, Trinidad and Tobago. 3SBio is headquartered in Shenyang, Liaoning, China.

 Gain a 360-degree view of 3SBio Inc and make more informed decisions for your business Gain a 360-degree view of 3SBio Inc and make more informed decisions for your business Find out more
Headquarters China
Address No. 3 A1, Road 10, Shenyang Economy & Technology, Development Zone, Liaoning , 110027
Website www.3sbio.com
Telephone 86 24 25811820
No of Employees 5,411
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange 1530 (HKG)
Revenue (2022) $1.1B 13.8% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -19.1% (2022 vs 2021)
Market Cap* $1.8B
Net Profit Margin (2022) XYZ -29.0% (2022 vs 2021)
* As of and is in US$
View 3SBio Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

3SBio Inc premium industry data and analytics

120+

Clinical Trials

Determine 3SBio Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

70+

Pipeline Drugs

Identify which of 3SBio Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for 3SBio Inc’s relevant decision makers and contact details.

40+

Catalyst Calendar

Proactively evaluate 3SBio Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Marketed Drugs

Understand 3SBio Inc’s commercialized product portfolio to stay one step ahead of the market.

10+

Sales & Consensus Forecasts

Understand the current and future drug revenue for 3SBio Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

8

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on 3SBio Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Services Brands
Oncology: Service: EPIAO
TPIAO CDMO Cipterbin
Cipterbin TPIAO
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand 3SBio Inc portfolio and identify potential areas for collaboration Understand 3SBio Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Regulatory Approval In January, Zhejiang Wansheng Pharmaceutical Co., Ltd received approval from the National Medical Products Administration by the PRC to launch Mandi (5% minoxidil) Foam for the treatment of androgenetic alopecia and alopecia areata.
2023 Contracts/Agreements In November, Shenyang 3SBio Co. and CStone Pharmaceuticals signed a license agreement and a production technology transfer agreement to obtain the anti-PD-1 monoclonal antibody nofazinlimab (CS1003) independently developed by CStone Pharmaceuticals in mainland China.
2023 Regulatory Approval In July, the company received New Drug Application (NDA) approval for Nafurafine Hydrochloride Orally Disintegrating Tablets.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters 3SBio Inc Kexing Biopharm Co Ltd Hubei Guangji Pharmaceutical Co Ltd CapitalBio Corp China Intertrade Ltd
Headquarters China China China China China
City Shenyang Ji'Nan Huanggang Beijing Shanghai
State/Province Liaoning Shandong Hubei Beijing Shanghai
No. of Employees 5,411 1,407 1,256 - -
Entity Type Public Public Public Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Lou Jing Executive Director; Chief Executive Officer; Chairman Executive Board 2014 60
He Xiang Chief Financial Officer Senior Management 2023 -
Zhenping Zhu, M.D., Ph.D President - Research & Development; Chief Scientific Officer Senior Management 2017 58
Su Dongmei Senior Vice President; Director Executive Board 2014 53
Ji Zhang Vice President Senior Management 2016 65
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into 3SBio Inc key executives to enhance your sales strategy Gain insight into 3SBio Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward